NR3C1 and prostate carcinoma: Long-term treatment with abiraterone is also associated with GR overexpression.[19] GR-mediated resistance to antiandrogen therapies is adaptive and reversible.[20] In prostate cancer, GR expression is initially silenced by a combination of enhancer of zeste 2 polycomb repressive complex 2 subunit–mediated repression and AR binding at the GR locus (Fig. 1).